Zacks Research Lifts Earnings Estimates for Editas Medicine

Key Points

• Zacks Research raised its Q3 2026 EPS estimate for Editas Medicine to a loss of $0.25 per share from a prior estimate of $0.34, while projecting a full-year 2026 loss of $0.90 per share.
• Editas exceeded expectations in its latest quarter, reporting a $0.15-per-share loss versus the consensus loss of $0.27 and revenue of $11.89 million against estimates of $2.85 million.
• Analyst sentiment remains generally positive, with five Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and a $5.50 price target; the stock opened at $3.30 and institutional investors own 71.9% of shares.

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Zacks Research boosted their Q3 2026 EPS estimates for shares of Editas Medicine in a research report issued to clients and investors on Wednesday, August 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their previous estimate of ($0.34). The consensus estimate for Editas Medicine's current full-year earnings is ($0.85) per share. Zacks Research also issued estimates for Editas Medicine's Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.90) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.30) EPS, FY2027 earnings at ($1.16) EPS, Q1 2028 earnings at ($0.33) EPS, Q2 2028 earnings at ($0.34) EPS and FY2028 earnings at ($1.34) EPS.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. The company had revenue of $11.89 million during the quarter, compared to the consensus estimate of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%.

Other equities analysts have also recently issued reports about the company. TD Cowen reiterated a "buy" rating on shares of Editas Medicine in a report on Wednesday, May 27th. Chardan Capital boosted their target price on Editas Medicine from $3.50 to $4.00 and gave the stock a "buy" rating in a research report on Tuesday, May 5th. Wall Street Zen upgraded shares of Editas Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of Editas Medicine from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Finally, LADENBURG THALM/SH SH began coverage on shares of Editas Medicine in a research note on Tuesday, August 18th. They issued a "buy" rating and a $6.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Editas Medicine currently has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Editas Medicine Stock Up 3.8%

NASDAQ EDIT opened at $3.30 on Friday. The stock's 50-day simple moving average is $2.99 and its two-hundred day simple moving average is $2.74. Editas Medicine has a twelve month low of $1.66 and a twelve month high of $4.54. The company has a market capitalization of $506.81 million, a price-to-earnings ratio of -4.40 and a beta of 2.14.

Insider Buying and Selling

In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,380 shares of the company's stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the completion of the transaction, the chief executive officer directly owned 248,313 shares in the company, valued at approximately $670,445.10. This represents a 5.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 21,503 shares of company stock valued at $57,910. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Editas Medicine

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Editas Medicine in the second quarter worth about $34,312,000. ADAR1 Capital Management LLC bought a new stake in Editas Medicine during the 2nd quarter valued at approximately $28,800,000. Renaissance Technologies LLC grew its holdings in shares of Editas Medicine by 30.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company's stock worth $9,811,000 after acquiring an additional 932,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Editas Medicine by 122.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company's stock worth $3,016,000 after acquiring an additional 1,430,000 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Editas Medicine by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company's stock worth $4,685,000 after acquiring an additional 244,574 shares in the last quarter. Hedge funds and other institutional investors own 71.90% of the company's stock.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source